Medulloblastoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Medulloblastoma – Drugs In Development, 2024 report and make more profitable business decisions.
Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty with walking and balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy, and radiation therapy.
The Medulloblastoma drugs in development market research report provide comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Medulloblastoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 70 molecules, with 57 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Medulloblastoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Medulloblastoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Medulloblastoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acrivon Therapeutics IncAurigene Oncology Ltd
Bayer AG
Beijing zhikangbo Medical Oncology Research Co Ltd
Bellicum Pharmaceuticals Inc
Biodexa Pharmaceuticals PLC
Biogenera SpA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cardiff Oncology Inc
Centessa Pharmaceuticals Plc
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chimerix Inc
Cincinnati Children's Hospital Medical Center
Curtana Pharmaceuticals Inc
Dalriada Therapeutics Inc
Dracen Pharmaceuticals Inc
Edison Oncology Holding Corp
Eisai Co Ltd
Gan & Lee Pharmaceuticals Co Ltd
Gennao Bio Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hudson Institute of Medical Research
Immunomic Therapeutics Inc
IMPACT Therapeutics Inc
Institute of Biotechnology and Pharmaceutical Research
Istari Oncology Inc
Kintor Pharmaceutical Ltd
Lumos Pharma Inc
MacroGenics Inc
Mana Therapeutics Inc
McMaster University
MimiVax LLC
Moleculin Biotech Inc
Mustang Bio Inc
Nanjing KAEDI Biotech Inc
Nascent Biotech Inc
Nino Jesus University Children's Hospital
Novartis AG
Nurix Therapeutics Inc
Nuvectis Pharma Inc
Ohio State University
Oncoheroes Biosciences Inc
OncoLife Therapeutics Pty Ltd
Oncurious NV
Orphelia Pharma SAS
Pfizer Inc
Progenics Pharmaceuticals Inc
ProLynx LLC
Sapience Therapeutics Inc
Shionogi & Co Ltd
Stanford University
Stanford University School of Medicine
Stemsynergy Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Treovir LLC
University of Connecticut
University of Florida
University of North Carolina
University of Utah
VBI Vaccines Inc
Vyriad Inc
Vyro Bio Inc
Winship Cancer Institute of Emory University
Wuhan Binhui Biopharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Medulloblastoma reports